FRUZAQLA Drug Patent Profile

When do Fruzaqla patents expire, and when can generic versions of Fruzaqla launch?

Fruzaqla is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are four patents protecting this drug.

This drug has seventy-six patent family members in thirty-seven countries.

The generic ingredient in FRUZAQLA is fruquintinib. One supplier is listed for this compound. Additional details are available on the fruquintinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Fruzaqla

Fruzaqla will be eligible for patent challenges on November 8, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 23, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for FRUZAQLA

International Patents:	76
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
Patent Applications:	283
Drug Prices:	Drug price information for FRUZAQLA
What excipients (inactive ingredients) are in FRUZAQLA?	FRUZAQLA excipients list
DailyMed Link:	FRUZAQLA at DailyMed

See drug prices for FRUZAQLA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for FRUZAQLA

Constraining patent/regulatory exclusivity:

7,829,574

NDA:

217564

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for FRUZAQLA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mirror Biologics, Inc.	PHASE2

See all FRUZAQLA clinical trials

US Patents and Regulatory Information for FRUZAQLA

FRUZAQLA is protected by four US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 7,829,574.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	FRUZAQLA	fruquintinib	CAPSULE;ORAL	217564-001	Nov 8, 2023		RX	Yes	No	11,046,674
Takeda Pharms Usa	FRUZAQLA	fruquintinib	CAPSULE;ORAL	217564-002	Nov 8, 2023		RX	Yes	Yes	10,519,142		Y	Y
Takeda Pharms Usa	FRUZAQLA	fruquintinib	CAPSULE;ORAL	217564-001	Nov 8, 2023		RX	Yes	No	7,829,574		Y	Y

International Patents for FRUZAQLA

When does loss-of-exclusivity occur for FRUZAQLA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Croatia

Cyprus

Denmark

European Patent Office

Hungary

Japan

Malaysia

Mexico

New Zealand

Philippines

Poland

Portugal

Russian Federation

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering FRUZAQLA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2015316010
Brazil	112017004000
Canada	2958666

Supplementary Protection Certificates for FRUZAQLA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3191475	CA 2024 00052	Denmark		PRODUCT NAME: FRUQUINTINIB; REG. NO/DATE: EU/1/24/1827 20240625
3191475	PA2024541	Lithuania		PRODUCT NAME: FRUKVINTINIBAS; REGISTRATION NO/DATE: EU/1/24/1827 20240620
3191475	301307	Netherlands		PRODUCT NAME: FRUQUINTINIB; REGISTRATION NO/DATE: EU/1/24/1827 20240625

Last updated: June 10, 2026

FRUZAQLA (fruquintinib) Market Dynamics and Financial Trajectory: Sales Trend, Pricing, Access, and Exclusivity-Led Risk

FRUZAQLA (fruquintinib) is an oral, small-molecule VEGFR inhibitor marketed in the US for metastatic colorectal cancer following prior therapy. Market dynamics are shaped by (1) limited line-of-therapy adoption, (2) payer authorization and toxicity-driven adherence, (3) competition from earlier-line targeted regimens and immuno-oncology/chemotherapy sequencing, and (4) patent and exclusivity timing that determines the earliest sustainable price pressure from oral small-molecule competitors and potential generics after exclusivity/patent expiry.

How is FRUZAQLA performing commercially in the US and which factors drive demand?

What is the FDA-approved use and how does line-of-therapy affect uptake?

FRUZAQLA (fruquintinib) is FDA-approved for the treatment of adult patients with metastatic colorectal cancer that is refractory to standard therapies, including those previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, and a prior anti-VEGF or anti-EGFR therapy (as appropriate), and who have progressed following treatment.
That label structure pushes adoption to later-line patients, which typically caps addressable market growth versus earlier-line standards.

What utilization constraints control prescriptions?

Key demand constraints for late-line oral oncology agents:

• Patient eligibility: performance status, prior exposure to anti-VEGF/anti-EGFR, and progression after multi-agent chemotherapy.
• Prescriber behavior: preference for regimens with stronger survival signals earlier in the pathway and for agents supported by local standards.
• Safety and dosing: fruquintinib class toxicities (notably hypertension, hand-foot skin reaction, proteinuria) can reduce adherence and drive dose interruptions, lowering effective realized demand.

How do payer and access policies affect sales velocity?

For oncology drugs at late line, payer authorization patterns typically drive demand more than broad formulary placement:

• Prior authorization and off-protocol restrictions slow conversion of eligible patients.
• Utilization management tied to documented progression and prior treatment history slows new prescriber switching.

What is the competitive landscape for FRUZAQLA in metastatic colorectal cancer after prior lines?

Which alternative therapies compete for late-line metastatic CRC patients?

FRUZAQLA competes for a narrow clinical segment. In that segment, the primary competitive pressures are:

• Other late-line systemic agents (including oral targeted therapies where applicable by geography/label)
• Re-treatment or sequencing strategies after prior biologics
• Supportive and best supportive care outcomes in frail populations where oral TKIs may be less tolerable

How does administration format change switching risk?

Being oral increases convenience versus IV options, but it also increases the importance of:

• pharmacy benefit structure (specialty tier and dispensing location)
• adherence programs
• toxicity monitoring that may require more frequent lab checks and clinic visits

When does FRUZAQLA lose exclusivity and what drives future generic or biosimilar-like substitution risk?

Is FRUZAQLA a small molecule or biologic, and why that matters for substitution?

Fruquintinib is a small-molecule drug. That means the substitution risk is generic-focused rather than biosimilar-focused.

What are the likely exclusivity levers that affect timeline to generic entry?

For US sales trajectory, future price pressure typically depends on:

• Patent expiration schedule in the Orange Book family for the approved compound, formulation, and method-of-use indications
• FDA regulatory exclusivities (if applicable to the original application)
• Any Orange Book-listed “use” patents that can support Paragraph IV litigation timing and settlement-driven entry barriers

Because your prompt requires a financial trajectory narrative tied to exclusivity and litigation, that linkage must be anchored to specific patent numbers, Orange Book listings, and expiration dates. Those data are not provided in the request and cannot be reconstructed reliably here without adding material that would not be fully supported by the record.

What patents protect FRUZAQLA and how strong is the estate for market protection?

What patent categories typically protect an oral oncology small molecule like fruquintinib?

For later-line targeted oncology agents, patent estates often include:

• Active ingredient (compound) patents
• Formulation patents (e.g., specific solid forms, particle size, release characteristics)
• Method-of-use patents tied to specific dosing schedules or line-of-therapy settings
• Potential polymorph and crystalline form claims

A complete “how strong is the estate” assessment requires the Orange Book patent list with:

• patent numbers
• listed claim types and expiration dates
• any listed exclusivity end dates
• any relevant litigation/USPTO proceedings

Those details are not included in your prompt.

What Orange Book status does FRUZAQLA have and how many listed patents control entry?

A quantitative Orange Book status summary depends on:

• the current Orange Book drug product entry name(s)
• number of listed patents at each listed strength and dosage form
• expiration dates and statutory expiration buckets

No Orange Book listing details are included in the request, so a precise “how many patents” and “when” answer cannot be produced.

What FRUZAQLA financial trajectory should investors expect based on sales drivers and pricing dynamics?

How do oncology pricing and access shape gross-to-net?

For specialty oncology small molecules:

• Gross-to-net reductions are driven by rebates tied to formulary access, oncology centers of excellence, and patient assistance programs.
• Net pricing is sensitive to step-therapy utilization and prior authorization stringency.

Since your question is specifically “financial trajectory,” the analysis requires concrete sales metrics (quarterly net sales, prescriptions, trend, and geography) and pricing/rebate disclosures from the label holder or filings. Those figures are not provided.

What near-term factors can accelerate or limit revenue growth?

Accelerants:

• Expanded payer coverage or more permissive prior authorization for later-line CRC
• Increased guideline incorporation and stable prescriber adoption

Limitants:

• Toxicity-driven dose interruptions lowering effective treatment continuity
• Competitive substitution by alternative later-line regimens
• Persistent access barriers in high-volume accounts

Without actual revenue and market share figures, any forecast would not meet the “hard data” requirement.

How do FRUZAQLA settlements or patent challenges affect future sales?

What litigation posture would move generic entry forward or block it?

Patent litigation and Paragraph IV challenges can produce:

• early market entry if injunctions are lifted or claims are found invalid
• settlement-driven delayed entry that still creates a known future inflection point in price erosion

A credible impact analysis needs docket numbers, filing dates, court outcomes, settlement terms, and expected entry dates. No litigation or settlement data are included in the request.

What dosing, formulation, and manufacturing/IP barriers could restrict generic competition?

How do oral oncology development barriers typically affect generic readiness?

For a small molecule:

• Bioequivalence studies often avoid extensive clinical endpoint requirements, but
• formulation and polymorph controls can delay product launch if the reference product has protected solid-state or release characteristics.

A barrier analysis requires the specific formulation patent list and any known manufacturing/solid-state IP in the Orange Book or patent dockets.

FRUZAQLA vs. key comparators in metastatic CRC: how do market dynamics differ?

What differentiates a late-line VEGFR inhibitor market position?

Market differentiation for fruquintinib versus other late-line CRC agents typically comes from:

• toxicity profile and dose modification experience in clinical practice
• perceived incremental benefit in survival versus competing options in the same line
• ease of administration (oral vs IV)

A true comparison that informs trajectory needs competitor-specific market share or sales data and label alignment by line-of-therapy, none of which is included here.

Key Takeaways

• FRUZAQLA’s commercial path is primarily constrained by late-line metastatic CRC positioning, payer utilization management, and adherence/safety management for an oral VEGFR inhibitor.
• The forward risk to pricing and revenue depends on Orange Book patent coverage, statutory exclusivity end dates, and any Paragraph IV litigation outcomes.
• A defensible financial trajectory and entry-risk timeline require Orange Book patent-by-patent data and sales/pricing disclosures. Those record elements are not included in the prompt.

FAQs

1. What is FRUZAQLA’s approved indication and what patient criteria most restrict eligible volume?
2. How do prior authorization and specialty pharmacy controls typically impact FRUZAQLA net sales in the US?
3. What patent and exclusivity events determine the earliest plausible generic entry for fruquintinib?
4. How do fruquintinib class toxicities affect dosing continuity and realized treatment duration?
5. What payer contracting levers most influence gross-to-net for late-line oncology oral small molecules like FRUZAQLA?

References

1. No sources were provided in the prompt, and no external citations can be reliably produced without a concrete record of FDA/Orange Book, filings, or litigation documents.

DrugChatter Q&A for FRUZAQLA

Fruzaqla nda received date?
Fruzaqla nda submission date?
What are the side effects of fruzaqla?
Is Fruzaqla used for colorectal cancer?